Company profile for AnaMar

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AnaMar is a privately held, clinical-stage biotech company developing a first-in-class, orally bioavailable, peripheral-acting 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine. AM1476 is a highly selective small molecule, which offers a unique dual-action potential to treat skin and lung manifestations of systemic sclerosis with a favorable safety profile. They are combining their innovative therapeutic plat...
AnaMar is a privately held, clinical-stage biotech company developing a first-in-class, orally bioavailable, peripheral-acting 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine. AM1476 is a highly selective small molecule, which offers a unique dual-action potential to treat skin and lung manifestations of systemic sclerosis with a favorable safety profile. They are combining their innovative therapeutic platforms with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment, using our heritage in diagnostics to ensure the best outcomes for those with fibrosis.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Sweden
Address
Address
Medicon Village, Scheeletorget 1, SE-223 81 Lund
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//news-release/2024/02/05/2823236/0/en/AnaMar-Announces-US-and-EU-Orphan-Drug-Designation-for-AM1476-for-Treating-Systemic-Sclerosis.html

GLOBENEWSWIRE
05 Feb 2024

https://www.globenewswire.com/news-release/2023/05/23/2673951/0/en/AnaMar-Announces-Positive-Phase-I-Data-for-its-Phase-II-Ready-Compound-AM1476-for-Treating-Fibrosis.html

GLOBENEWSWIRE
23 May 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty